Product Description: DY268 is a farnesoid X receptor (FXR) antagonist (IC50=7.5 nM). It inhibits FXR transactivation in a cell-based assay with an IC50 value of 468 nM. DY268 can be used in the study of drug-induced liver injury (DILI)[1][2].
Applications: Metabolism-sugar/lipid metabolism
Formula: C30H32N4O5S
References: [1]Yu DD, Lin W, Forman BM, Chen T. Identification of trisubstituted-pyrazol carboxamide analogs as novel and potent antagonists of farnesoid X receptor. Bioorg Med Chem. 2014 Jun 1;22(11):2919-38. /[2]Kyounghwa Jung, et al. Farnesoid X Receptor Activation Impairs Liver Progenitor Cell-Mediated Liver Regeneration via the PTEN-PI3K-AKT-mTOR Axis in Zebrafish. Hepatology. 2021 Jul;74(1):397-410./[3]Leah M Norona, et al. In vitro assessment of farnesoid X receptor antagonism to predict drug-induced liver injury risk. Arch Toxicol. 2020 Sep;94(9):3185-3200.
CAS Number: 1609564-75-1
Molecular Weight: 560.66
Compound Purity: 99.32
Research Area: Metabolic Disease
Solubility: DMSO : 50 mg/mL (ultrasonic;warming;heat to 60°C)
Target: FXR
English
Deutsch
